

L Number	Hits	Search Text	DB	Time stamp
1	2365	(544/262,360,365,383).CCLS.	USPAT; US-PGPUB	2004/08/10 11:37
2	2	((544/262,360,365,383).CCLS.) AND ("[4,3-d]" OR piperazin-1-ylsol\$2onyl)	USPAT; US-PGPUB	2004/08/10 11:38
3	2	((544/262,360,365,383).CCLS.) AND ("[4,3-d]" OR \$piperazin-1-ylsol\$2onyl)	USPAT; US-PGPUB	2004/08/10 11:39
4	375	((544/262,360,365,383).CCLS.) AND ("[4,3-d]" OR \$piperazin-1-yl)	USPAT; US-PGPUB	2004/08/10 11:39
5	2	((544/262,360,365,383).CCLS.) AND ("[4,3-d]" OR \$piperazin-1-ylsol\$)	USPAT; US-PGPUB	2004/08/10 11:39

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal61ltxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	May 12	EXTEND option available in structure searching
NEWS	4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in Cplus
NEWS	6	May 27	Cplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02	Cplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS EXPRESS		JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:13:18 ON 10 AUG 2004

=> file reg

FILE 'REGISTRY' ENTERED AT 14:14:44 ON 10 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 AUG 2004 HIGHEST RN 724701-07-9

DICTIONARY FILE UPDATES: 9 AUG 2004 HIGHEST RN 724701-07-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.



Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10723659.str



chain nodes :
13 15 16 17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-15 4-13 7-13 8-19 10-16 11-18 12-20 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-6 1-15 2-3 3-4 4-5 4-13 5-6 7-8 7-12 7-13 8-9 8-19 9-10 10-11
10-16 11-12 11-18 12-20 16-17

G1:CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

G2:N,CH

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 14:15:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 192 TO ITERATE


100.0% PROCESSED 192 ITERATIONS 12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3009 TO 4671
PROJECTED ANSWERS: 33 TO 447

L2 12 SEA SSS SAM L1

=> d scan

L2 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 3-Pyridinecarboxamide, N-[5-(aminocarbonyl)-3-ethyl-1-[(1-methyl-1H-imidazol-2-yl)methyl]-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI)
MF C25 H35 N9 O5 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN


IN 3-Pyridinecarboxamide, N-[5-(aminocarbonyl)-3-(1,1-dimethylethyl)-1-(2-pyridinylmethyl)-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI)

MF C28 H38 N8 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN Piperazine, 1-[(3,4-dimethoxyphenyl)sulfonyl]-4-methyl- (9CI)
 MF C13 H20 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN 1H-Pyrazole-5-carboxamide, 4-[[[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]methylene]amino]-1-methyl-3-propyl- (9CI)
 MF C22 H32 N6 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L2 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN 1-Piperidinecarboxylic acid, 4-[3-(aminocarbonyl)-4-[[[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]carbonyl]amino]-5-ethyl-1H-pyrazol-1-yl]-, 1,1-dimethylethyl ester (9CI)
 MF C30 H46 N8 O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN Piperazine, 1-[(3-cyano-4-ethoxyphenyl)sulfonyl]-4-methyl- (9CI)
 MF C14 H19 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 12 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
 IN Piperazine, 1-[[2-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)ethyl]-4,5-dimethoxyphenyl)sulfonyl]-4-methyl- (9CI)
 MF C27 H29 N3 O6 S





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\Stnexp\Queries\10723659.str



chain nodes :

13 15 16 17 18 19 20

ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
1-15 4-13 7-13 8-19 10-16 11-18 12-20 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
1-2 1-6 1-15 2-3 3-4 4-5 4-13 5-6 7-8 7-12 7-13 8-9 8-19 9-10 10-11
10-16 11-12 11-18 12-20 16-17

G1:CH3,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu

G2:N,CH

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS

L3 STRUCTURE UPLOADED

=> s l3 full

FULL SEARCH INITIATED 14:18:34 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3986 TO ITERATE

100.0% PROCESSED 3986 ITERATIONS

181 ANSWERS

SEARCH TIME: 00.00.01

L4 181 SEA SSS FUL L3

=> file caplus

FILE 'CAPLUS' ENTERED AT 14:18:42 ON 10 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Aug 2004 VOL 141 ISS 7

FILE LAST UPDATED: 9 Aug 2004 (20040809/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4

L5 39 L4

=> sort l5 py

SORT ENTIRE ANSWER SET? (Y)/N:.

PROCESSING COMPLETED FOR L5

L6 39 SORT L5 PY

=> d 1-15 cbib pi hitstr


L6 ANSWER 1 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

1998:13695 Document No. 128:75412 Process for preparation of Sildenafil by cyclization. Dunn, Peter James; Wood, Albert Shaw (Pfizer Limited, UK; Pfizer Research and Development Company, N.V./s.A.). Eur. Pat. Appl. EP 812845 A1 19971217, 18 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO. (English). CODEN: EPXXDW. APPLICATION: EP 1997-303832 19970604. PRIORITY: GB 1996-12514 19960614.


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 812845	A1	19971217	EP 1997-303832	19970604
EP 812845	B1	19990714		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO				
TW 391961	B	20000601	TW 1997-86106681	19970519
NO 9702481	A	19971215	NO 1997-2481	19970530
EP 916675	A2	19990519	EP 1998-123740	19970604
EP 916675	A3	19990714		
EP 916675	B1	20030730		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LV, FI, RO				
AT 182150	E	19990715	AT 1997-303832	19970604
ES 2134051	T3	19990916	ES 1997-303832	19970604
AT 246194	E	20030815	AT 1998-123740	19970604
PT 916675	T	20031128	PT 1998-123740	19970604
ES 2201397	T3	20040316	ES 1998-123740	19970604
IL 121000	A1	20000229	IL 1997-121000	19970605
IL 125411	A1	20000229	IL 1997-125411	19970605
US 5955611	A	19990921	US 1997-869532	19970606
IN 187350	A	20020330	IN 1997-DE1548	19970610
SK 283894	B6	20040406	SK 2001-1783	19970610
SK 283895	B6	20040406	SK 2001-1784	19970610
SK 283896	B6	20040406	SK 2001-1786	19970610
SK 283897	B6	20040406	SK 2001-1787	19970610
SK 283893	B6	20040406	SK 1997-743	19970610
CA 2207694	AA	19971214	CA 1997-2207694	19970612
CA 2207694	C	19991123		
CZ 290942	B6	20021113	CZ 1997-1811	19970612
ZA 9705259	A	19971215	ZA 1997-5259	19970613
AU 9724878	A1	19971218	AU 1997-24878	19970613
AU 697684	B2	19981015		
CN 1168376	A	19971224	CN 1997-113261	19970613
CN 1106399	B	20030423		
JP 10081688	A2	19980331	JP 1997-156422	19970613
JP 2866841	B2	19990308		
HR 970326	B1	20001031	HR 1997-970326	19970613
BR 9703580	A	19981110	BR 1997-3580	19970616
JP 11171879	A2	19990629	JP 1998-271067	19980925

JP 3058863	B2	20000704		
NO 9805064	A	19971215	NO 1998-5064	19981030
US 6066735	A	20000523	US 1999-360128	19990723
CN 1282740	A	20010207	CN 2000-120054	20000705
IN 187317	A	20020323	IN 2001-DE517	20010424
IN 187318	A	20020323	IN 2001-DE518	20010424
IN 187319	A	20020323	IN 2001-DE519	20010424
IN 187320	A	20020323	IN 2001-DE520	20010424

IT **194602-23-8P 200575-15-1P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (process for preparation of clin. quality sildenafil by cyclization)
 RN 194602-23-8 CAPLUS
 CN Benzoic acid, 2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 200575-15-1 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, 4-[[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-1-methyl-3-propyl- (9CI) (CA INDEX NAME)




L6 ANSWER 2 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN
 1997:390578 Document No. 127:5005 Preparation of sulfamoylphenyl alkanoates as elastase inhibitors. Nakae, Takahiko; Kato, Masashi; Fujita, Takehito; Kawabata, Kazuhito; Ohno, Hiroyuki (Ono Pharmaceutical Co., Ltd., Japan). Eur. Pat. Appl. EP 769498 A1 19970423, 270 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1996-307048 19960927.


PRIORITY: JP 1995-272058 19950927; JP 1996-45663 19960224.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 769498	A1	19970423	EP 1996-307048	19960927
	EP 769498	B1	20040317		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09165365	A2	19970624	JP 1995-272058	19950927
	JP 09278742	A2	19971028	JP 1996-271341	19960924
	JP 2881688	B2	19990412		
	JP 10251218	A2	19980922	JP 1998-111630	19960924
	AU 9665837	A1	19970410	AU 1996-65837	19960925
	AU 714025	B2	19991216		
	ZA 9608069	A	19970520	ZA 1996-8069	19960925
IT	NO 9604045	A	19970401	NO 1996-4045	19960926
	CA 2186665	AA	19970328	CA 1996-2186665	19960927
	190251-73-1P 190255-77-7P				
RN	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
CN	(preparation of sulfamoylphenyl alkanoates as elastase inhibitors)				
	190251-73-1 CAPLUS				
	Benzeneacetic acid, α -ethyl-4-(1-pyrrolidinyl)-, 2-methyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl ester, dihydrochloride (9CI) (CA INDEX NAME)				

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 190255-77-7 CAPLUS
CN Benzeneacetic acid, α -ethyl-4-(1-pyrrolidinyl)-,
2-methyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl ester (9CI) (CA INDEX
NAME)

PAGE 1-A




PAGE 2-A



L6 ANSWER 3 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN
 1998:721699 Document No. 129:330741 Preparation of pyrazolopyrimidinones as inhibitors of type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction.. Bunnage, Mark Edward; Mathias, John Paul; Street, Stephen Derek Albert; Wood, Anthony (Pfizer Ltd., UK; Pfizer Inc.). PCT Int. Appl. WO 9849166 A1 19981105, 157 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2.
 APPLICATION: WO 1998-EP2257 19980410. PRIORITY: GB 1997-8406 19970425; GB 1997-15380 19970722; GB 1997-22954 19971030.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9849166	A1	19981105	WO 1998-EP2257	19980410
W:			AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG	
TW 524805	B	20030321	TW 1998-87102657	19980224
AU 9876445	A1	19981124	AU 1998-76445	19980410
AU 730670	B2	20010308		
EP 977756	A1	20000209	EP 1998-924132	19980410
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO	
TR 9902646	T2	20000522	TR 1999-9902646	19980410
JP 2000510485	T2	20000815	JP 1998-546543	19980410
BR 9810233	A	20001017	BR 1998-10233	19980410
NZ 338075	A	20001027	NZ 1998-338075	19980410
CA 2288910	C	20030624	CA 1998-2288910	19980410
AP 1002	A	20010814	AP 1998-1228	19980423
W:			KE, UG, ZM, ZW, GM, MW, BW	
ZA 9803478	A	19991025	ZA 1998-3478	19980424
HR 980222	B1	20031231	HR 1998-980222	19980424
US 6723719	B1	20040420	US 1999-402229	19990929
MX 9909762	A	20000430	MX 1999-9762	19991022
NO 9905211	A	19991025	NO 1999-5211	19991025


JP 2004196820 A2 20040715 JP 2004-59879 20040303
 IT **194602-23-8P 215299-33-5P 215299-34-6P**
215299-79-9P 215299-80-2P 215299-81-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrazolopyrimidinones as inhibitors of type 5 cyclic
 guanosine 3',5'-monophosphate phosphodiesterase for the treatment of
 sexual dysfunction)
 RN 194602-23-8 CAPLUS
 CN Benzoic acid, 2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]- (9CI) (CA
 INDEX NAME)



RN 215299-33-5 CAPLUS
 CN Benzoic acid, 2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]-,
 monohydrochloride, compd. with N,N-diethylethanamine (1:1) (9CI) (CA
 INDEX NAME)


CM 1

CRN 194602-23-8
 CMF C14 H20 N2 O5 S




CM 2

CRN 121-44-8
 CMF C6 H15 N




RN 215299-34-6 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, 4-[[2-ethoxy-5-[(4-methyl-1-
 piperazinyl)sulfonyl]benzoyl]amino]-1-(phenylmethyl)-3-propyl- (9CI) (CA
 INDEX NAME)




RN 215299-79-9 CAPLUS

CN Benzoic acid, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-propoxy- (9CI) (CA INDEX NAME)



RN 215299-80-2 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-ethyl-4-[[5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-propoxybenzoyl]amino]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 215299-81-3 CAPLUS

CN Benzoic acid, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-propoxy-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 215299-79-9


CMF C16 H24 N2 O5 S



CM 2

CRN 75-75-2

CMF C H4 O3 S




L6 ANSWER 4 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN
 1998:605272 Document No. 129:330622 Palladium(0)-catalyzed arylations using pyrrole- and indole-2-boronic acids. Johnson, Christopher N.; Stemp, Geoffrey; Anand, Neel; Stephen, Susanna C.; Gallagher, Timothy (SmithKline Beecham Pharmaceuticals, Harlow, CM19 5AW, UK). Synlett (9), 1025-1027 (English) 1998. CODEN: SYNLES. ISSN: 0936-5214. OTHER SOURCES: CASREACT 129:330622. Publisher: Georg Thieme Verlag.

IT **215187-22-7**
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (palladium-catalyzed arylation using pyrrole- and indoleboronates)

RN 215187-22-7 CAPLUS

CN Piperazine, 1-[(3-bromo-4-methoxyphenyl)sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 5 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN
 1998:568589 Document No. 129:175653 Preparation of benzenesulfonamides as elastase inhibitors. Nakae, Takahiko; Kato, Masashi; Fujita, Takehito; Kawabata, Kazuhito; Ohno, Hiroyuki (Ono Pharmaceutical Co., Ltd., Japan). U.S. US 5795890 A 19980818, 150 pp. (English). CODEN: USXXAM.
 APPLICATION: US 1996-718722 19960924. PRIORITY: JP 1995-272568 19950927; JP 1996-45663 19960208.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5795890	A	19980818	US 1996-718722	19960924
	JP 09165365	A2	19970624	JP 1995-272058	19950927
	JP 09278742	A2	19971028	JP 1996-271341	19960924
	JP 2881688	B2	19990412		
	JP 10251218	A2	19980922	JP 1998-111630	19960924
	AU 9665837	A1	19970410	AU 1996-65837	19960925
	AU 714025	B2	19991216		
	ZA 9608069	A	19970520	ZA 1996-8069	19960925
	NO 9604045	A	19970401	NO 1996-4045	19960926
	CA 2186665	AA	19970328	CA 1996-2186665	19960927
	US 5998410	A	19991207	US 1998-31192	19980226


IT **190251-73-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzenesulfonamides as elastase inhibitors)


RN 190251-73-1 CAPLUS

CN Benzeneacetic acid, α -ethyl-4-(1-pyrrolidinyl)-,
2-methyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl ester, dihydrochloride
(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● 2 HCl

L6 ANSWER 6 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

1999:795656 Document No. 132:35712 Preparation of quinazolinone inhibitors of cGMP phosphodiesterase. Macor, John E.; Rotella, David P.; Weller, Harold N., III; Cushman, David W.; Yevich, Joseph P. (Bristol-Myers Squibb Company, USA). PCT Int. Appl. WO 9964004 A1 19991216, 141 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US12485 19990602. PRIORITY: US 1998-88538 19980608.


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9964004	A1	19991216	WO 1999-US12485	19990602
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6087368	A	20000711	US 1999-322678	19990528
CA 2334970	AA	19991216	CA 1999-2334970	19990602
AU 9943332	A1	19991230	AU 1999-43332	19990602
AU 746586	B2	20020502		
EP 1085871	A1	20010328	EP 1999-955422	19990602
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			

IT **215299-79-9P 252233-57-1P 252233-58-2P 252233-60-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazolinone inhibitors of cGMP phosphodiesterase)


RN 215299-79-9 CAPLUS

CN Benzoic acid, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-propoxy- (9CI) (CA INDEX NAME)




RN 252233-57-1 CAPLUS

CN Benzoic acid, 5-[(4-methyl-1-piperazinyl)sulfonyl]-2-propoxy-, methyl ester (9CI) (CA INDEX NAME)




RN 252233-58-2 CAPLUS

CN Benzoic acid, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-propoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 252233-60-6 CAPLUS

CN Benzoic acid, 5-[(4-methyl-1-piperazinyl)sulfonyl]-2-propoxy- (9CI) (CA INDEX NAME)




1999:729792 Document No. 132:279187 Synthesis of sildenafil. Shen, Jing; You, Congchao; Wu, Song (Institute of Materia Medica, Chinese Academy of Materia Medica and Peking Union Medical College, Beijing, 100050, Peop. Rep. China). Zhongguo Yaowu Huaxue Zazhi, 9(3), 220-222 (Chinese) 1999. CODEN: ZYHZEJ. ISSN: 1005-0108. Publisher: Zhongguo Yaowu Huaxue Zazhi Bianjibu.

IT **194602-23-8P 200575-15-1P 263710-03-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of sildenafil)


RN 194602-23-8 CAPLUS

CN Benzoic acid, 2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 200575-15-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 4-[[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-1-methyl-3-propyl- (9CI) (CA INDEX NAME)



RN 263710-03-8 CAPLUS

CN Benzoyl chloride, 2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L6 ANSWER 8 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN


1999:691100 Document No. 131:310644 Preparation of pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction. Bunnage, Mark Edward; Mathias, John Paul; Street, Stephen Derek Albert; Wood, Anthony (Pfizer Inc., USA; Pfizer Limited). PCT Int. Appl. WO 9954333 A1 19991028, 221 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-IB519 19990325. PRIORITY: GB 1998-8315 19980420; GB 1998-14187 19980630.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9954333	A1	19991028	WO 1999-IB519	19990325
W:			AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
CA 2329077	AA	19991028	CA 1999-2329077	19990325
AU 9927425	A1	19991108	AU 1999-27425	19990325
AU 748352	B2	20020606		
BR 9909808	A	20001226	BR 1999-9808	19990325
TR 200003039	T2	20010122	TR 2000-200003039	19990325
EP 1073658	A1	20010207	EP 1999-907805	19990325
EP 1073658	B1	20030813		
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO	
JP 2002512248	T2	20020423	JP 2000-544672	19990325
AT 247117	E	20030815	AT 1999-907805	19990325
EP 1371647	A2	20031217	EP 2003-13988	19990325
EP 1371647	A3	20040728		
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL	
PT 1073658	T	20031231	PT 1999-907805	19990325


	CN 1134441	B	20040114	CN 1999-807288	19990325
	ES 2203078	T3	20040401	ES 1999-907805	19990325
	AP 1022	A	20011114	AP 1999-1514	19990415
	W: BW, GM, GH, KE, MW, SD, UG, ZM, ZW				
	ZA 9902793	A	20001019	ZA 1999-2793	19990419
	US 6251904	B1	20010626	US 1999-402242	19990929
	NO 2000005255	A	20001219	NO 2000-5255	20001019
	HR 2000000712	A1	20010630	HR 2000-712	20001020
	BG 104949	A	20010629	BG 2000-104949	20001115
	US 2001039271	A1	20011108	US 2001-845420	20010430
	US 6458951	B2	20021001		
	JP 2004099620	A2	20040402	JP 2003-390698	20031120
IT	247582-64-5P 247582-65-6P 247582-66-7P 247582-68-9P 247582-69-0P 247582-70-3P 247582-71-4P 247582-73-6P 247582-74-7P 247582-75-8P 247582-76-9P 247582-77-0P 247582-78-1P 247582-79-2P 247582-85-0P 247582-87-2P 247582-91-8P 247582-92-9P 247582-93-0P 247582-94-1P 247582-95-2P 247582-96-3P 247583-06-8P 247583-07-9P 247583-08-0P 247583-13-7P 247583-14-8P 247583-19-3P 247583-20-6P 247583-21-7P 247583-22-8P 247583-23-9P 247583-24-0P 247583-25-1P 247583-26-2P 247583-30-8P 247583-34-2P 247583-40-0P 247583-43-3P 247583-45-5P 247583-46-6P 247583-48-8P 247583-50-2P 247583-52-4P 247583-64-8P 247583-65-9P 247583-66-0P 247583-87-5P 247583-89-7P 247583-91-1P 247583-93-3P 247583-94-4P 247583-95-5P 247583-96-6P 247583-97-7P 247583-98-8P 247583-99-9P 247584-00-5P 247584-01-6P 247584-07-2P 247584-11-8P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction)				
RN	247582-64-5 CAPLUS				
CN	Piperazine, 1-[[5-bromo-6-(2-methoxyethoxy)-3-pyridinyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)				




RN 247582-65-6 CAPLUS
 CN Piperazine, 1-[[5-bromo-6-(2-ethoxyethoxy)-3-pyridinyl]sulfonyl]-4-ethyl-
 (9CI) (CA INDEX NAME)




RN 247582-66-7 CAPLUS

CN Piperazine, 1-[[5-bromo-6-(3-methoxypropoxy)-3-pyridinyl]sulfonyl]-4-ethyl-
(9CI) (CA INDEX NAME)

RN 247582-68-9 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-,
ethyl ester (9CI) (CA INDEX NAME)


RN 247582-69-0 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-(2-
methoxyethoxy)-, ethyl ester (9CI) (CA INDEX NAME)

RN 247582-70-3 CAPLUS


CN 3-Pyridinecarboxylic acid, 2-(2-ethoxyethoxy)-5-[(4-ethyl-1-

piperazinyl)sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 247582-71-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-(3-methoxypropoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 247582-73-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 247582-74-7 CAPLUS


CN 3-Pyridinecarboxylic acid, 2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 247582-75-8 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-(2-methoxyethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 247582-76-9 CAPLUS


CN 3-Pyridinecarboxylic acid, 2-(2-ethoxyethoxy)-5-[(4-ethyl-1-piperazinyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 247582-77-0 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-(3-methoxypropoxy)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 247582-78-1 CAPLUS
 CN 3-Pyridinecarbonyl chloride, 2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 247582-79-2 CAPLUS
 CN 3-Pyridinecarbonyl chloride, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-(2-methoxyethoxy)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 247582-85-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-ethyl-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 247582-87-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-ethyl-1-(2-pyridinylmethyl)-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247582-91-8 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-[(4-methyl-1-piperazinyl)sulfonyl]-2-propoxy-, methyl ester (9CI) (CA INDEX NAME)



RN 247582-92-9 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-[(4-methyl-1-piperazinyl)sulfonyl]-2-propoxy-
(9CI) (CA INDEX NAME)

RN 247582-93-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-ethyl-1-(2-pyridinylmethyl)-
1H-pyrazol-4-yl]-5-[(4-methyl-1-piperazinyl)sulfonyl]-2-propoxy- (9CI)
(CA INDEX NAME)


RN 247582-94-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-propyl-1-(2-pyridinylmethyl)-
1H-pyrazol-4-yl]-5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-(2-methoxyethoxy)-
(9CI) (CA INDEX NAME)




RN 247582-95-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-propyl-1-(2-pyridinylmethyl)-1H-pyrazol-4-yl]-2-(2-ethoxyethoxy)-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247582-96-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-propyl-1-(2-pyridinylmethyl)-1H-pyrazol-4-yl]-5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-(3-methoxypropoxy)- (9CI) (CA INDEX NAME)




RN 247583-06-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-(aminocarbonyl)-3-ethyl-1-(2-pyridinylmethyl)-1H-pyrazol-4-yl]-5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RN 247583-07-9 CAPLUS

CN Piperazine, 1-[[5-bromo-6-[2-methoxy-1-(methoxymethyl)ethoxy]-3-pyridinyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 247583-08-0 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-[2-methoxy-1-(methoxymethyl)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 247583-13-7 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-[2-methoxy-1-(methoxymethyl)ethoxy]-, sodium salt (9CI) (CA INDEX NAME)



● Na


RN 247583-14-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-propyl-1-(2-pyridinylmethyl)-1H-pyrazol-4-yl]-5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-[2-methoxy-1-(methoxymethyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 247583-19-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-propyl-1-(2-pyridinylmethyl)-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247583-20-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-propoxy-, methyl ester (9CI) (CA INDEX NAME)




RN 247583-21-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-propoxy- (9CI) (CA INDEX NAME)




RN 247583-22-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-propyl-1-(2-pyridinylmethyl)-1H-pyrazol-4-yl]-5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-propoxy- (9CI) (CA INDEX NAME)




RN 247583-23-9 CAPLUS

CN Piperazine, 1-[[5-bromo-6-[2-(phenylmethoxy)ethoxy]-3-pyridinyl]sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 247583-24-0 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-[2-(phenylmethoxy)ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 247583-25-1 CAPLUS


CN 3-Pyridinecarboxylic acid, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-[2-(phenylmethoxy)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 247583-26-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-propyl-1-(2-pyridinylmethyl)-1H-pyrazol-4-yl]-5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-[2-(phenylmethoxy)ethoxy]- (9CI) (CA INDEX NAME)




RN 247583-30-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-ethyl-1-(phenylmethyl)-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247583-34-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-ethyl-1-[(1-methyl-1H-imidazol-2-yl)methyl]-1H-pyrazol-4-yl]-5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RN 247583-40-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-propyl-1-(3-pyridazinylmethyl)-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247583-43-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-(aminocarbonyl)-3-propyl-1-(2-pyrimidinylmethyl)-1H-pyrazol-4-yl]-5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RN 247583-45-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-propyl-1-(2-pyrimidinylmethyl)-1H-pyrazol-4-yl]-5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-(2-methoxyethoxy)- (9CI) (CA INDEX NAME)




RN 247583-46-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-(aminocarbonyl)-3-propyl-1-(2-pyrimidinylmethyl)-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247583-48-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-(aminocarbonyl)-3-propyl-1-(2-pyridinylmethyl)-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247583-50-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-(aminocarbonyl)-3-ethyl-1-[(1-methyl-1H-imidazol-2-yl)methyl]-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 247583-52-4 CAPLUS


CN 3-Pyridinecarboxamide, N-[5-(aminocarbonyl)-1-[(1-methyl-1H-imidazol-2-yl)methyl]-3-propyl-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 247583-64-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-1-[2-(4-morpholinyl)ethyl]-5-propyl-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 247583-65-9 CAPLUS


CN 3-Pyridinecarboxamide, N-[5-(aminocarbonyl)-3-(1,1-dimethylethyl)-1-(2-pyridinylmethyl)-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 247583-66-0 CAPLUS


CN 3-Pyridinecarboxamide, N-[5-(aminocarbonyl)-1-[2-(4-morpholinyl)ethyl]-3-propyl-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A







RN 247583-87-5 CAPLUS
CN Piperazine, 1-[(5-bromo-6-ethoxy-3-pyridinyl)sulfonyl]-4-methyl- (9CI)
(CA INDEX NAME)



RN 247583-89-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 247583-91-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 247583-93-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-1-methyl-5-propyl-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247583-94-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-ethyl-1-methyl-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247583-95-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-1-methyl-5-propyl-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247583-96-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-1,5-diethyl-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247583-97-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-ethyl-1-[1-(2-pyridinyl)ethyl]-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247583-98-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-ethyl-1-[(6-methyl-2-pyridinyl)methyl]-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247583-99-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-ethyl-1-[(6-methoxy-2-pyridinyl)methyl]-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247584-00-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-(aminocarbonyl)-3-ethyl-1-methyl-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247584-01-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-(aminocarbonyl)-1-methyl-3-propyl-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 247584-07-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-ethyl-1-[(1-methyl-1H-imidazol-2-yl)methyl]-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 247584-11-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(aminocarbonyl)-5-propyl-1-(2-pyrimidinylmethyl)-1H-pyrazol-4-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

2000:818584 Document No. 134:115917 Optimization of Substituted

N-3-Benzylimidazoquinazolinone Sulfonamides as Potent and Selective PDE5 Inhibitors. Rotella, David P.; Sun, Zhong; Zhu, Yeheng; Krupinski, John; Pongrac, Ronald; Seliger, Laurie; Normandin, Diane; Macor, John E.

(Departments of Discovery Chemistry and Metabolic and Cardiovascular Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-5400, USA). Journal of Medicinal Chemistry, 43(26), 5037-5043 (English) 2000. CODEN: JMCMAR. ISSN: 0022-2623. OTHER SOURCES: CASREACT 134:115917. Publisher: American Chemical Society.


IT **215299-79-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors)

RN 215299-79-9 CAPLUS

CN Benzoic acid, 5-[(4-ethyl-1-piperazinyl)sulfonyl]-2-propoxy- (9CI) (CA INDEX NAME)



L6 ANSWER 10 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

2000:595512 Document No. 133:335213 Polymer-supported reagents for multi-step organic synthesis: application to the synthesis of sildenafil. Baxendale, I. R.; Ley, S. V. (Department of Chemistry, University of

Cambridge, Cambridge, CB2 1EW, UK). Bioorganic & Medicinal Chemistry Letters, 10(17), 1983-1986 (English) 2000. CODEN: BMCLE8. ISSN: 0960-894X. OTHER SOURCES: CASREACT 133:335213. Publisher: Elsevier Science Ltd..


IT **304435-84-5P**

RL: BYP (Byproduct); PREP (Preparation)

(polymer-supported reagents for the synthesis of sildenafil)

RN 304435-84-5 CAPLUS

CN Benzoic acid, 2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT **194602-23-8P 200575-15-1P 304435-85-6DP,**


polymer-supported

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(polymer-supported reagents for the synthesis of sildenafil)


RN 194602-23-8 CAPLUS

CN Benzoic acid, 2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 200575-15-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 4-[[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-1-methyl-3-propyl- (9CI) (CA INDEX NAME)




RN 304435-85-6 CAPLUS
 CN Piperazine, 1-[[[3-[(1H-benzotriazol-1-yloxy)carbonyl]-4-ethoxyphenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 11 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN
 2000:351203 Document No. 132:347588 An improved process for preparing a therapeutically active pyrazolopyrimidinone derivative (sildenafil). Chaudhari, Deoram Totaram; Deshpande, Pandurang Balwantrao; Khan, Rashid Abdul Rehman (Orchid Chemicals & Pharmaceuticals Ltd., India). Eur. Pat. Appl. EP 1002798 A1 20000524, 17 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO. (English). CODEN: EPXXDW. APPLICATION: EP 1998-122031 19981120.
 PATENT NO. KIND DATE APPLICATION NO. DATE

 PI EP 1002798 A1 20000524 EP 1998-122031 19981120
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
 IT **200575-15-1P**
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (improved process for preparing a therapeutically active pyrazolopyrimidinone derivative (sildenafil))
 RN 200575-15-1 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, 4-[[[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-1-methyl-3-propyl- (9CI) (CA INDEX NAME)]




L6 ANSWER 12 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN
 2000:291043 Document No. 132:308353 Preparation of pyrazolopyrimidinones as
 cGMP phosphodiesterase inhibitors. Bunnage, Mark Edward; Maw, Graham
 Nigel; Rawson, David James; Wood, Anthony; Mathias, John Paul; Street,
 Stephen Derek Albert (Pfizer Limited, UK; Pfizer Inc.). PCT Int. Appl. WO
 2000024745 A1 20000504, 197 pp. DESIGNATED STATES: W: AE, AL, AM, AT,
 AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI,
 GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI,
 CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL,
 PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO
 1999-IB1706 19991019. PRIORITY: GB 1998-23102 19981023; GB 1998-23101
 19981023.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000024745	A1	20000504	WO 1999-IB1706	19991019
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9959956	A1	20000515	AU 1999-59956	19991019
BR 9915532	A	20010814	BR 1999-15532	19991019
EP 1123296	A1	20010816	EP 1999-970992	19991019
EP 1123296	B1	20030917		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002528456	T2	20020903	JP 2000-578315	19991019
AT 250063	E	20031015	AT 1999-970992	19991019
PT 1123296	T	20031231	PT 1999-970992	19991019
ES 2205945	T3	20040501	ES 1999-970992	19991019
US 6333330	B1	20011225	US 1999-426554	19991022
IT 194602-23-8				

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of pyrazolopyrimidinones as cGMP phosphodiesterase inhibitors)

RN 194602-23-8 CAPLUS

CN Benzoic acid, 2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




IT 247582-68-9P 247582-73-6P 247582-78-1P
 263710-03-8P 264920-27-6P 265663-85-2P
 265663-87-4P 265663-88-5P 265663-89-6P
 265664-59-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of pyrazolopyrimidinones as cGMP phosphodiesterase inhibitors)


RN 247582-68-9 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-,
 ethyl ester (9CI) (CA INDEX NAME)




RN 247582-73-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-
 (9CI) (CA INDEX NAME)




RN 247582-78-1 CAPLUS

CN 3-Pyridinecarbonyl chloride, 2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 263710-03-8 CAPLUS
 CN Benzoyl chloride, 2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 264920-27-6 CAPLUS
 CN Piperazine, 1-[(5-bromo-6-ethoxy-3-pyridinyl)sulfonyl]-4-ethyl- (9CI) (CA
 INDEX NAME)




RN 265663-85-2 CAPLUS
 CN 1H-Pyrazole-5-carboxylic acid, 3-(aminocarbonyl)-4-[[2-ethoxy-5-[(4-methyl-
 1-piperazinyl)sulfonyl]benzoyl]amino]-1-(phenylmethyl)-, methyl ester
 (9CI) (CA INDEX NAME)




RN 265663-87-4 CAPLUS

CN 1H-Pyrazole-3,5-dicarboxamide, 4-[[[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]carbonyl]amino]-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 265663-88-5 CAPLUS

CN 1H-Pyrazole-3,5-dicarboxamide, 4-[[[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]carbonyl]amino]-N3-methyl-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 265663-89-6 CAPLUS

CN 1H-Pyrazole-3,5-dicarboxamide, 4-[[[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]carbonyl]amino]-N5,1-dimethyl- (9CI)
(CA INDEX NAME)



RN 265664-59-3 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-(aminocarbonyl)-4-[[[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-3-pyridinyl]carbonyl]amino]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 13 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN
 2000:277701 Document No. 132:293775 Preparation of pyrazolopyrimidinones as
 cGMP PDE5 inhibitors for the treatment of sexual dysfunction. Bunnage,
 Mark Edward; Street, Stephen Derek Albert; Mathias, John Paul; Wood,
 Anthony (Pfizer Inc., USA; Pfizer Limited). Eur. Pat. Appl. EP 995751 A2
 20000426, 40 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB,
 GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO. (English).
 CODEN: EPXXDW. APPLICATION: EP 1999-308158 19991015. PRIORITY: GB
 1998-23103 19981023.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 995751	A2	20000426	EP 1999-308158	19991015
	EP 995751	A3	20001018		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9905109	A	20000926	BR 1999-5109	19991022
	US 6407114	B1	20020618	US 1999-425095	19991022
	JP 2000128884	A2	20000509	JP 1999-302064	19991025
	MX 9909816	A	20000630	MX 1999-9816	19991025


IT **247582-68-9P 247582-73-6P 247582-78-1P**
263710-03-8P 264920-22-1P 264920-24-3P
264920-25-4P 264920-26-5P 264920-27-6P
264920-28-7P 264920-29-8P 264920-30-1P
264920-31-2P 264920-34-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyrazolopyrimidinones as cGMP PDE5 inhibitors for the treatment of sexual dysfunction)

RN 247582-68-9 CAPLUS


CN 3-Pyridinecarboxylic acid, 2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 247582-73-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-
(9CI) (CA INDEX NAME)


RN 247582-78-1 CAPLUS

CN 3-Pyridinecarbonyl chloride, 2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]-
, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 263710-03-8 CAPLUS


CN Benzoyl chloride, 2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 264920-22-1 CAPLUS

CN Benzamide, N-[4-cyano-3-(phenylmethyl)-1-propyl-1H-pyrazol-5-yl]-2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 264920-24-3 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 5-[[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-1-ethyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 264920-25-4 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 5-[[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-3-[(phenylmethoxy)methyl]-1-propyl- (9CI) (CA INDEX NAME)




RN 264920-26-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, 5-[[2-ethoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-3-methyl-1-propyl- (9CI) (CA INDEX NAME)




RN 264920-27-6 CAPLUS

CN Piperazine, 1-[(5-bromo-6-ethoxy-3-pyridinyl)sulfonyl]-4-ethyl- (9CI) (CA INDEX NAME)




RN 264920-28-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(aminocarbonyl)-1-ethyl-3-pyrazinyl-1H-pyrazol-5-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 264920-29-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(aminocarbonyl)-1-propyl-3-pyrazinyl-1H-pyrazol-5-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 264920-30-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(aminocarbonyl)-1-ethyl-3-phenyl-1H-pyrazol-5-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 264920-31-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(aminocarbonyl)-1-ethyl-3-[(phenylmethoxy)methyl]-1H-pyrazol-5-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 264920-34-5 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-(aminocarbonyl)-1-cyclopentyl-3-ethyl-1H-pyrazol-5-yl]-2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 14 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN
 2000:259773 Document No. 132:279229 Preparation of pyrazolo[4,3-d]pyrimidin-
 7-ones. Dunn, Peter James; Levett, Philip Charles (Pfizer Limited, UK;
 Pfizer Research and Development Company, N.V./S.A.). Eur. Pat. Appl. EP
 994115 A2 20000419, 20 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES,
 FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO.
 (English). CODEN: EPXXDW. APPLICATION: EP 1999-307996 19991011.
 PRIORITY: GB 1998-22238 19981012.


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 994115	A2	20000419	EP 1999-307996	19991011
	EP 994115	A3	20000524		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6207829	B1	20010327	US 1999-415440	19991008
	CN 1255497	A	20000607	CN 1999-123918	19991009
	CN 1473831	A	20040211	CN 2003-2003142738	19991009
	AU 9953581	A1	20000413	AU 1999-53581	19991011
	AU 756463	B2	20030116		
	NO 9904943	A	20000413	NO 1999-4943	19991011
	MX 9909326	A	20000430	MX 1999-9326	19991011
	KR 2000028987	A	20000525	KR 1999-43836	19991011
	BR 9905092	A	20000808	BR 1999-5092	19991011
	ZA 9906412	A	20010411	ZA 1999-6412	19991011
	BG 63205	B1	20010629	BG 1999-103794	19991011
	EG 22630	A	20030531	EG 1999-1269	19991011
	JP 2000119273	A2	20000425	JP 1999-290099	19991012
	EE 9900507	A	20000615	EE 1999-507	19991012
	EE 4192	B1	20031215		
	HR 990318	A1	20000630	HR 1999-990318	19991012
	HR 990318	B1	20040630		
	TR 9902541	A2	20000721	TR 1999-9902541	19991012
	US 2001009962	A1	20010726	US 2001-761376	20010116
	US 2003069422	A1	20030410	US 2002-253029	20020923
IT	263897-16-1P 263897-17-2P				
	RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of pyrazolo[4,3-d]pyrimidin-7-ones)				
RN	263897-16-1 CAPLUS				
CN	Benzoic acid, 2-methoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]- (9CI) (C				

INDEX NAME)



RN 263897-17-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 4-[[2-methoxy-5-[(4-methyl-1-piperazinyl)sulfonyl]benzoyl]amino]-1-methyl-3-propyl- (9CI) (CA INDEX NAME)



L6 ANSWER 15 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN

2000:176119 Document No. 132:342802 N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction. Rotella, David P.; Sun, Zhong; Zhu, Yeheng; Krupinski, John; Pongrac, Ronald; Seliger, Laurie; Normandin, Diane; Macor, John E. (Discovery Chemistry and Cardiovascular Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-5400, USA). Journal of Medicinal Chemistry, 43(7), 1257-1263 (English) 2000. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.


IT **269731-53-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazoquinazolinones as potent and selective PDE5 inhibitors and potential agents for treatment of erectile dysfunction)

RN 269731-53-5 CAPLUS

CN Benzoic acid, 5-[(4-methyl-1-piperazinyl)sulfonyl]-2-propoxy-, lithium salt (9CI) (CA INDEX NAME)



● Li

=>

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:.

STN INTERNATIONAL LOGOFF AT 14:23:24 ON 10 AUG 2004